The new P2Y12 inhibitor cangrelor unreliably inhibits heparin-induced platelet aggregation in the presence of HIT antibodies, an in vitro study

被引：0
|
作者：
Scala, E. [1 ]
Gerschheimer, C. [2 ,3 ]
Gomez, F. J. [2 ,3 ]
Alberio, L. [2 ,3 ,4 ]
Marcucci, C. [1 ,4 ]
机构：
[1] Lausanne Univ Hosp CHUV, Dept Anesthesiol, Lausanne, Switzerland
[2] Lausanne Univ Hosp CHUV, Div Hematol, Lausanne, Switzerland
[3] Lausanne Univ Hosp CHUV, Cent Hematol Lab, Lausanne, Switzerland
[4] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2019年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FC 19
引用
收藏
页码：8S / 8S
页数：1
相关论文
共 50 条
  • [1] The new P2Y12 inhibitor cangrelor unreliably inhibits heparin-induced platelet aggregation in the presence of HIT antibodies, an in vitro study
    Scala, E.
    Gerschheimer, C.
    Gomez, F. J.
    Marcucci, C.
    Alberio, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 22 - 22
  • [2] The new P2Y12 inhibitor cangrelor unreliably inhibits heparin-induced platelet aggregation in the presence of HIT antibodies, an in vitro study
    Emmanuelle, Scala
    Christiane, Gerschheimer
    Javier, Gomez Francisco
    Carlo, Marcucci
    Lorenzo, Alberio
    SWISS MEDICAL WEEKLY, 2019, 149 : 31S - 31S
  • [3] Potential and Limitations of the New P2Y12Inhibitor, Cangrelor, in Preventing Heparin-Induced Platelet Aggregation During Cardiac Surgery: An In Vitro Study
    Scala, Emmanuelle
    Gerschheimer, Christiane
    Gomez, Francisco J.
    Alberio, Lorenzo
    Marcucci, Carlo
    ANESTHESIA AND ANALGESIA, 2020, 131 (02): : 622 - 630
  • [4] The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor
    Bouman, Heleen J.
    van Werkum, Jochem W.
    Rudez, Goran
    Leebeek, Frank W. G.
    Kruit, Adrian
    Hackeng, Christian M.
    ten Berg, Jurrien M.
    de Maat, Moniek P. M.
    Ruven, Henk J. T.
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (02) : 379 - 386
  • [5] The influence of variation in the P2Y12 receptor gene on the magnitude of in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor
    Bouman, H. J.
    van Werkum, J. W.
    Rudez, G.
    Leebeek, F. W. G.
    Kruit, A.
    Hackeng, C. M.
    ten Berg, J. M.
    de Maat, M. P. M.
    Ruven, H. J. T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 587 - 588
  • [6] Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood
    R. M. Bell
    V. Sivaraman
    S. P. Kunuthur
    M. V. Cohen
    J. M. Downey
    D. M. Yellon
    Cardiovascular Drugs and Therapy, 2015, 29 : 415 - 418
  • [7] Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood
    Bell, R. M.
    Sivaraman, V.
    Kunuthur, S. P.
    Cohen, M. V.
    Downey, J. M.
    Yellon, D. M.
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (05) : 415 - 418
  • [8] Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro
    Judge, Heather M.
    Buckland, Robert J.
    Jakubowski, Joseph A.
    Storey, Robert F.
    PLATELETS, 2016, 27 (03) : 191 - 195
  • [9] Effect of immature platelets on ADP-induced platelet reactivity after infusion of the P2Y12 receptor inhibitor cangrelor and transitioning to oral P2Y12 inhibitors
    Stratz, C.
    Nuhrenberg, T.
    Kleiner, P.
    Leggewie, S.
    Neumann, F. J.
    Hochholzer, W.
    Trenk, D.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S23 - S23
  • [10] No effect of platelet supplementation to reverse the P2Y12 inhibitor ticagrelor: an in vitro study
    Martin, A. -C.
    Berndt, C.
    Gaussem, P.
    Gouin-Thibault, I.
    Siguret, V.
    Le Bonniec, B.
    Godier, A.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1170 - 1170
12345